NDAINTRAVENOUSSOLUTION
Approved
Sep 2022
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
3/8 — Basic
NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE (norepinephrine bitartrate) by Baxter is (alpha-adrenergic action) and an inotropic stimulator of the heart and dilator of coronary arteries (beta-adrenergic action). First approved in 2022.
Drug data last refreshed 18h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Norepinephrine bitartrate in 0.9% sodium chloride is a catecholamine vasopressor agent administered intravenously for acute hypotension management. It works through dual alpha-adrenergic (vasoconstriction) and beta-adrenergic (inotropic and coronary vasodilation) mechanisms to restore blood pressure and cardiac output. This product is indicated for patients in critical care settings requiring immediate hemodynamic support.
Peak13.0 years to LOE
Peak lifecycle product with stable critical care market demand; commercial teams focused on hospital formulary penetration and ICU clinician relationships rather than growth expansion.
Mechanism of Action
(alpha-adrenergic action) and an inotropic stimulator of the heart and dilator of coronary arteries (beta-adrenergic action).
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on norepinephrine bitartrate offers stable, long-term career stability in a mature critical care franchise with predictable revenue streams and established market dynamics. Opportunities are concentrated in hospital formulary management, clinician education, and outcomes research rather than launch intensity or indication expansion.
Hospital Account ManagerCritical Care Sales Specialist
Worked on NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE at Baxter? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.